TY - JOUR
T1 - Efficacy and prognosis of chronic myeloid leukemia treated with imatinib mesylate in a Chinese population
AU - Zhao, Yanmin
AU - Liu, Lizhen
AU - Wang, Yingjia
AU - Wu, Gongqiang
AU - Lai, Xiaoyu
AU - Cao, Weijie
AU - Luo, Yi
AU - Tan, Yamin
AU - Shi, Jimin
AU - Xie, Wanzhuo
AU - Ye, Xiujin
AU - Cai, Zhen
AU - Lin, Maofang
AU - Huang, He
N1 - Funding Information:
Acknowledgments We are grateful to Prof. Bruce Iain C (Department of Physiology, School of Medicine, Zhejiang University) for critically reviewing the manuscript. We also thank Novartis (Basel, Switzerland) and the Max Foundation (Edmonds, WA) for providing the patients with imatinib mesylate. The work was funded by the Major Science & Technology Program of Zhejiang Province (2006C13022) and Health Professions Scientific Research Program (200802027).
PY - 2009/5
Y1 - 2009/5
N2 - There is limited data from developing countries on the current status of imatinib treatment for chronic myeloid leukemia (CML), thus we retrospectively analyzed 116 Chinese CML patients who received imatinib between 2003 and 2008. The response rates for 102 patients in chronic phase were: complete hematologic, 94.1%; complete cytogenetic, 69.6%; and complete molecular response, 54.9%. For 14 patients in the accelerated phase, the respective response rates were 85.7, 35.7 and 28.6%. The 3-year progression-free survival and 5-year overall survival were 73.3 and 74.8%. Although skin hypopigmentation occurs as the most common side effect (77.6%), imatinib is still well tolerated. In addition to the known pretreatment characteristics of spleen size, leukocyte and platelet counts, disease phase and Sokal scores, we found that delayed therapy, variant Philadelphia chromosome translocations and IM-related grade 3/4 leucopenia were associated with an inferior cytogenetic response. Four factors emerged as predictors of disease progression: molecular response, cytogenetic response, disease phase and disease duration prior to imatinib treatment, but only the latter three remained significant after multivariate analysis. The results indicate that the suboptimal outcome in Chinese patients is associated with delayed imatinib therapy, so the importance of the optimal treatment opportunity for CML should be emphasized.
AB - There is limited data from developing countries on the current status of imatinib treatment for chronic myeloid leukemia (CML), thus we retrospectively analyzed 116 Chinese CML patients who received imatinib between 2003 and 2008. The response rates for 102 patients in chronic phase were: complete hematologic, 94.1%; complete cytogenetic, 69.6%; and complete molecular response, 54.9%. For 14 patients in the accelerated phase, the respective response rates were 85.7, 35.7 and 28.6%. The 3-year progression-free survival and 5-year overall survival were 73.3 and 74.8%. Although skin hypopigmentation occurs as the most common side effect (77.6%), imatinib is still well tolerated. In addition to the known pretreatment characteristics of spleen size, leukocyte and platelet counts, disease phase and Sokal scores, we found that delayed therapy, variant Philadelphia chromosome translocations and IM-related grade 3/4 leucopenia were associated with an inferior cytogenetic response. Four factors emerged as predictors of disease progression: molecular response, cytogenetic response, disease phase and disease duration prior to imatinib treatment, but only the latter three remained significant after multivariate analysis. The results indicate that the suboptimal outcome in Chinese patients is associated with delayed imatinib therapy, so the importance of the optimal treatment opportunity for CML should be emphasized.
KW - Chinese population
KW - Chronic myeloid leukemia
KW - Cytogenetic response
KW - Hypopigmentation
KW - Imatinib
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=67449123241&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67449123241&partnerID=8YFLogxK
U2 - 10.1007/s12185-009-0292-7
DO - 10.1007/s12185-009-0292-7
M3 - Article
C2 - 19350352
AN - SCOPUS:67449123241
SN - 0925-5710
VL - 89
SP - 445
EP - 451
JO - International journal of hematology
JF - International journal of hematology
IS - 4
ER -